MedTrace Logo

Psoas Sciatic Blockade for Knee Arthroplasty

NCT03088371 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-11-22

No results posted yet for this study

Summary

Objectives: To compare the efficacy of continuous combined psoas sciatic block as a sole anaesthetic technique with conventional combined spinal epidural anesthesia for patients undergoing total knee arthroplasty.

Subjects and Method: Eighty patients ASA (American society of anaesthesiologists classification) I to III with age range from 50 to 65 years old and scheduled for total knee replacement were included in the study. Subjects were divided into two groups; the first group (Pso/sci) received ultrasound guided with the use of nerve locator continuous psoas sciatic block and the second group (CSE) received combined spinal epidural anesthesia. Onset of sensory and motor block time, hemodynamic changes, contra-lateral spread, first time need for analgesia, incidence of complications, and patient and surgeon satisfactions were recorded.

Conditions

Interventions

DRUG

Bupivacaine 0.25%

For psoas sciatic block.

OTHER

Pajunk Needle

For local anaesthesia application in psoas sciatic block

OTHER

Portex combined spinal epidural kit

For combined spinal epidural anaesthesia

DRUG

Lidocaine 1%

For psoas sciatic block.

DRUG

Bupivacaine 0.5%

For spinal anaesthesia in combined spinal epidural anaesthesia.

DRUG

Lidocaine 2 %

For psoas sciatic block in the post-operative period

DRUG

Bupivacaine 0.125 %

For combined spinal epidural in the post-operative period.

Sponsors & Collaborators

  • Menoufia University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-10
Primary Completion
2016-06-14
Completion
2016-09-22

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03088371 on ClinicalTrials.gov